---
title: "Erasca’s KRAS inhibitor ERAS-0015 draws investor focus amid limited data"
id: "stat-news-4-stat-in-cancer-drug-development-the-spotlight-shifts-onto-erasca-s-kras"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-4-stat-in-cancer-drug-development-the-spotlight-shifts-onto-erasca-s-kras"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/11/19/erasca-kras-targeted-treatment-new-data-pancreatic-cancer/?utm_campaign=rss"
published_at: "2026-11-19T11:30:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Erasca’s KRAS inhibitor ERAS-0015 draws investor focus amid limited data
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-4-stat-in-cancer-drug-development-the-spotlight-shifts-onto-erasca-s-kras
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/11/19/erasca-kras-targeted-treatment-new-data-pancreatic-cancer/?utm_campaign=rss)
- **Published At:** 2026-11-19T11:30:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Erasca asserts it discovered a more potent, better-tolerated pan-RAS inhibitor in China and has branded that molecule **ERAS-0015**. - The company compared its candidate to Revolution Medicines’ **Rasonque** in promotional statements; investigators reported only limited early-stage data so far. - Erasca has released sparse results via press releases; the study team has not published full datasets or methods in the material provided. - CEO Jonathan Lim signaled to investors that the drug produced an approximately “4-handle” (about 40%) overall response rate in second-line-plus **pancreatic cancer**, language that the market has noticed. - Market valuations differ sharply: Erasca’s market value sits near $5 billion versus Revolution’s roughly $35 billion, a gap that investors interpret as potential acquisition opportunity. - The company is due to present additional data on **ERAS-0015** at the EORTC-NCI-AACR “Triple” meeting in Barcelona; meeting embargo rules limit previewed details. - Data already disclosed remain insufficient to independently verify comparative potency, tolerability, or trial design; the source did not report dosing, sample size, trial endpoints, or safety profile. - The public record in the story leaves key clinical questions unanswered — namely independent confirmation, detailed efficacy metrics, safety signals, and full methodology for the reported responses. - Investors are reacting to a combination of promotional claims and valuation asymmetry rather than a complete published evidence set. - The article notes the remainder of the reporting is behind a STAT+ subscription paywall; the public summary reflects only what the source reported.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/11/19/erasca-kras-targeted-treatment-new-data-pancreatic-cancer/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/19/erasca-kras-targeted-treatment-new-data-pancreatic-cancer/?utm_campaign=rss) [research](https://www.statnews.com/topic/research/) [FDA](https://www.statnews.com/topic/fda/) [HHS](https://www.statnews.com/topic/hhs/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT@JPM27](https://www.statnews.com/jpm-conference-stat-events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Trust in Science](https://www.statnews.com/trust-in-science/) * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Madness 2027](https://www.statnews.com/feature/stat-madness/apply/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) China's Biotech Powerhouse 25 We ranked the 25 most valuable publicly traded Chinese drugmakers [ See the list ](https://www.statnews.com/china-biotech-index-powerhouse-25/) [STAT Plus](https://www.statnews.com/stat-plus/)Opinion[Adam’s Biotech Scorecard](https://www.statnews.com/category/adams-biotech-scorecard/) # In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment ## Plus: Biotech entrepreneur Bob Langer on the ‘AI will cure all diseases’ dustup * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/19/erasca-kras-targeted-treatment-new-data-pancreatic-cancer/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_499879090-645x645.jpeg) Adobe ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) Nov. 19, 2026 Senior Writer, Biotech ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 1. [](https://x.com/adamfeuerstein "X") adam.feuerstein@statnews.com Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast [The Readout Loud](https://www.statnews.com/category/readout-loud/) and author of the newsletter [Adam’s Biotech Scorecard.](https://www.statnews.com/signup/scorecard/) You can reach Adam on Signal at stataf.54. _This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter._ _Sign up[here](https://www.statnews.com/signup/scorecard/) to get it delivered to your inbox. And [subscribe to STAT+](https://www.statnews.com/stat-plus/) to get an unabridged version, with exclusive content._ Erasca’s pitch is straightforward: The U.S.-based biotech says it went to China and found a more potent, better-tolerated pan-RAS inhibitor than Revolution Medicines’ Rasonque. To date, Erasca has backed up its claim with scant data from an early-stage study disseminated via press releases. The story might be true, it might not be, but for now that’s less important to investors than Erasca’s $5 billion market value, which is a fraction of the $35 billion carried by Revolution Medicines. The valuation disparity makes sense given Revolution’s lead, but it also stokes speculation that Erasca could be an attractive takeover target. Advertisement On Friday, the company is presenting another slug of data on its drug, called ERAS-0015, at the EORTC-NCI-AACR “Triple” meeting in Barcelona. Erasca knows what it’s presenting already, obviously, so without breaking the meeting’s embargo policy, CEO Jonathan Lim has been signaling to investors at investment banking conferences that a “4-handle” — Wall Street lingo for 40%-ish — overall response rate from ERAS-0015 in second line-plus pancreatic cancer would be “meaningfully different” from Rasonque. [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [Artificial intelligence](https://www.statnews.com/topic/artificial-intelligence/), [biotechnology](https://www.statnews.com/topic/biotechnology/), [drug development](https://www.statnews.com/topic/drug-development/), [Pharmaceuticals](https://www.statnews.com/topic/pharmaceuticals/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 1. [](https://x.com/adamfeuerstein "X") 2. Senior Writer, Biotech 1. [](https://x.com/adamfeuerstein "X") 2. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast [The Readout Loud](https://www.statnews.com/category/readout-loud/) and author of the newsletter [Adam’s Biotech Scorecard.](https://www.statnews.com/signup/scorecard/) You can reach Adam on Signal at stataf.54. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2024/03/Biotech-Scorecard-Logo-NoSTAT-640x290.png) ### STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2025/09/TheWorkup_Illustration_MollyFerguson_093025-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [I’m a cardiologist. I’m a little puzzled about the blockbuster new study on deprescribing statins](https://www.statnews.com/2026/11/19/deprescribing-statins-study-stream-trial-aha-questions/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_1874804219-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Beyond statins, one drug lowered heart attack risk by 20%](https://www.statnews.com/2026/11/05/repatha-vs-zetia-cholesterol-study-heart-attack-risk/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/11/GettyImages-2260732407-2-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Before midterm losses, MAHA spent on itself instead of candidates](https://www.statnews.com/2026/11/19/maha-pac-how-it-spent-money-insiders-candidates-nonprofit/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/11/image-9-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Epic Systems defends competitive practices, promises to let AI access its records](https://www.statnews.com/2026/11/18/epic-defends-competitive-practices-promises-ai-access-to-records/) 5. ![](https://www.statnews.com/wp-content/uploads/2025/12/AP25240773010054-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Cassidy rejects Trump’s pick to lead NSF, saying he failed to ‘stand up for science’](https://www.statnews.com/2026/11/18/bill-cassidy-rejects-jim-oneill-lead-national-science-foundation/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/10/STATatHLTH_Wordpress_CalendarImage-80x80.jpg) STAT@hlth. A Dose of Reality on EHRs and AI In-person Nov 18 ](https://www.statnews.com/event/stathlth-a-dose-of-reality-on-ehrs-and-ai/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/BTE2027_Wordpress_CalendarImage-80x80.jpg) 2027 Breakthrough Summit East New York City, NY Mar 18 ](https://www.statnews.com/event/2027-stat-breakthrough-summit-east/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2024/09/GettyImages-1237273640-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics](https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/) 2. ![](https://www.statnews.com/wp-content/uploads/2017/01/AP80889059-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Federal judge issues final ruling blocking U.S. plan to limit visa length for grad students, postdocs](https://www.statnews.com/2026/11/16/judge-rejects-visa-limits-international-researchers-upholds-duration-of-status-policy/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_587333568_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In a win for MAHA, FDA creates new regulatory category for the supplement NAC](https://www.statnews.com/2026/11/16/fda-proposes-new-category-supplement-nac/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_391451620_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug](https://www.statnews.com/pharmalot/2026/11/10/former-lilly-rep-claims-she-was-fired-for-complaining-about-marketing-of-mounjaro-diabetes-drug/) 5. ![](https://www.statnews.com/wp-content/uploads/2019/09/AP_060324030695-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves novel Bayer drug to reduce recurrence of stroke](https://www.statnews.com/2026/11/09/cardiovascular-stroke-recurrence-bayer-drug-fda-approval/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard November 12, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: What to know about Biogen’s big lupus study readout ](https://www.statnews.com/2026/11/12/biogen-lupus-litifilimab-what-to-know/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard November 12, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem ](https://www.statnews.com/2026/11/12/alnylam-amvuttra-heart-drug-growth/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard November 5, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: A closer look at ProMis Neurosciences and its Alzheimer’s drug ](https://www.statnews.com/2026/11/05/promis-neurosciences-alzheimers-disease-acumen-vertex-kidney-drug/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard October 29, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Vertex kidney disease drug scrutinized for infection risk ](https://www.statnews.com/2026/10/29/biotech-news-vertex-kidney-disease-drug-scrutinized-for-infection-risk/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech October 22, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: What to expect from the Moderna-Merck cancer vaccine data reveal ](https://www.statnews.com/2026/10/22/esmo-2026-what-to-know-ahead-of-moderna-merck-cancer-vaccine-data-reveal/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: What to know about Biogen's big lupus study readout ](https://www.statnews.com/2026/11/12/biogen-lupus-litifilimab-what-to-know/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: As Epic’s dominance grows, its iron grip is choking innovation in health technology ](https://www.statnews.com/2026/10/28/epic-systems-ehr-dominance-health-tech-antitrust-scrutiny/) By [Casey Ross](https://www.statnews.com/staff/casey-ross/) and [Brittany Trang](https://www.statnews.com/staff/brittany-trang/) 3. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: After death in gene therapy trial for a brain disease, progress is reported ](https://www.statnews.com/2026/11/17/capsida-gene-therapy-trial-death-follow-up-investigation/) By [Jason Mast](https://www.statnews.com/staff/jason-mast/) 4. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Sellas' experimental blood cancer immunotherapy reduced risk of death in clinical trial ](https://www.statnews.com/2026/11/17/sellas-blood-cancer-immunotherapy-succeeds-clinical-trial/) By [
## Related Clinical Research

- [Merck partners with Isomorphic Labs to discover small-molecule oncology candidates](https://medichelpline.com/clinical-feed/stat-news-3-stat-merck-isomorphic-labs-partner-to-develop-oncology-drug-candidates.md)
- [FDA details why it rejected Summit’s lung cancer drug](https://medichelpline.com/clinical-feed/stat-news-1-stat-fda-discloses-reasons-for-rejecting-summit-drug.md)
- [U.S. POINTER: Structured lifestyle program slows brain aging and cardiometabolic risk over 24 mont](https://medichelpline.com/clinical-feed/medical-news-today-0-combining-physical-mental-and-social-habits-slows-brain-aging-in-2-year-trial.md)
- [Ultra-processed foods linked to MRI signs of vascular brain injury in middle-aged adults](https://medichelpline.com/clinical-feed/medical-news-today-0-ultra-processed-foods-may-be-harming-brain-health-in-otherwise-healthy-adults.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.